SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Report abuse about a comment

Sponsors involved as well

One should not forget that CROs still work for sponsors and do not conduct trials for themselves. The fact that sales outside the US have grown that much demonstrates that the big pharma , which is by far the biggest client of global CROs, is more and more interested in selling its products outside the US market. This is particularly true for emerging countries such as Brasil or India. And since it is way easier to get registration and to sell its drug, in Brasil for example, once trials have been conducted in the country, sponsors ask for CROs to have an international expansion. Therefore it is not only the CROs that are globalising, it is the whole pharma industry.

Posted by Guillaume Miara
30 August 2011 | 15h30

Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.

Your name *
Your email *

We will not publish your email on the site

Reason *

Back to: Over 50% of sales at top CROs now made outside US; report

Spotlight

Trial transparency's impact opaque say drug and CRO industry experts at PCT in Barcelona

Trial transparency's impact opaque say drug and CRO industry experts at PCT in Barcelona

Making clinical trials more open has pros and cons for CROs and drugmakers according to experts from...

In-house manufacturing ‘trounces’ outsourcing spend, report finds

In-house manufacturing investments ‘trounce’ outsourcing spend, report finds

Biopharma companies are not likely to outsource a larger chunk of their manufacturing than they have in...

Top 7 CROs soon to exceed 50% market share, Parexel CFO says

Top 7 CROs soon to exceed 50% market share, Parexel CFO says

As PRA Health Services goes public this week, nearly all of the top CROs are now public...

China sets new requirements for hospitals running clinical trials

China sets new requirements for hospitals running clinical trials

The Chinese authorities are supplementing their current regulations around clinical trials with new mandates for the hospitals...

INC stock launches up almost 10% as CEO says business as usual
Exclusive interview

INC stock launches up almost 10% as CEO says business as usual

The IPO boom for CROs is kicking off with INC Research’s stock offering, which as of Friday...